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Abstract
Background: Sarcopenia, the critical depletion of skeletal muscle mass, is an independent prognostic factor in
several tumor entities for treatment-related toxicity and survival. In esophageal cancer, there have been conflicting
results regarding the value of sarcopenia as prognostic factor, which may be attributed to the heterogeneous
patient populations and the retrospective nature of previous studies. The aim of our study was therefore to
determine the impact of sarcopenia on prospectively collected specific outcomes in a subgroup of patients treated
within the phase III study SAKK 75/08 with trimodality therapy (induction chemotherapy, radiochemotherapy and
surgery) for locally advanced esophageal cancer.
Methods: Sarcopenia was assessed by skeletal muscle index at the 3rd lumbar vertebra (L3) in cross-sectional
computed tomography scans before induction chemotherapy, before radiochemotherapy and after neoadjuvant
therapy in a subgroup of 61 patients from four centers in Switzerland. Sarcopenia was determined by previously
established cut-off values (Martin et al., PMID: 23530101) and correlated with prospectively collected outcomes
including treatment-related toxicity, postoperative morbidity, treatment feasibility and survival.
Results: Using the published cut-off values, the prevalence of sarcopenia increased from 29.5% before treatment to
63.9% during neoadjuvant therapy (p < 0.001). Feasibility of neoadjuvant therapy and surgery was not different in
initially sarcopenic and non-sarcopenic patients. We observed in sarcopenic patients significantly increased grade ≥
3 toxicities during chemoradiation (83.3% vs 52.4%, p = 0.04) and a non-significant trend towards increased
postoperative complications (66.7% vs 42.9%, p = 0.16). No difference in survival according to sarcopenia could be
observed in this small study population.
Conclusions: Trimodality therapy in locally advanced esophageal cancer is feasible in selected patients with
sarcopenia. Neoadjuvant chemoradiation increased the percentage of sarcopenia. Sarcopenic patients are at higher
risk for increased toxicity during neoadjuvant radiochemotherapy and showed a non-significant trend to more
postoperative morbidity.
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Background
Sarcopenia, the critical depletion of skeletal muscle mass,
is an independent predictor of survival in several tumor
entities and can lead to a better risk stratification for treat-
ment-related complications than age and body mass index
(BMI) [1–3]. The advantage of sarcopenia as prognostic
factor is that it can be easily assessed on cross-sectional
computed tomography (CT) imaging which is usually per-
formed in cancer patients for staging [3].
Initial weight loss and nutritional status are known for a
long time as adverse prognostic factors for surgical
complications and overall survival in esophageal cancer
patients [4–6]. In recent years, there have been a rapidly
increasing number of publications on the role of sarcope-
nia in esophageal cancer [7, 8]. Although current meta-
analyses suggest an inferior survival for sarcopenic
patients with esophageal cancer [7, 8], the results of the
individual patient series are conflicting, most likely due to
the heterogeneity of the investigated patient populations.
While sarcopenic patients had an inferior outcome in
some series [9, 10], this correlation was not observed in
more selected groups such as patients receiving trimodal-
ity therapy [11, 12] or in patients younger than 65 years
[13]. However, there is still a lack of data on the role of
sarcopenia in homogeneous patient groups which have
been selected by stringent study inclusion criteria.
Likewise, it is currently controversial whether sarcope-
nia is a risk factor for increased adverse events during
neoadjuvant treatment and surgery [7]. Most previous re-
ports have focused on postoperative morbidity and mor-
tality, and data on the role of sarcopenia specifically in
patients receiving trimodality treatment is scarce [12, 14].
Finally, it is also debated whether previously published
cut-off values for sarcopenia are applicable to all cancer
patient populations [7].
The aim of our study was therefore to assess the impact
of sarcopenia in patients with locally advanced esophageal
cancer treated with induction chemotherapy, neoadjuvant
radiochemotherapy and surgery with or without cetuxi-
mab within the phase III trial SAKK 75/08 [15].
Methods
The intergroup phase III trial SAKK 75/08 randomized
300 patients with locally advanced esophageal cancer to
receive trimodality therapy with or without cetuximab at
53 European centers between May 2010 and December
2013. Trimodality therapy consisted of induction chemo-
therapy (two cycles of docetaxel 75 mg/m2, cisplatin 75
mg/m2) and neoadjuvant radiochemotherapy (45 Gy; do-
cetaxel 20 mg/m2 and cisplatin 25 mg/m2 weekly for 5
weeks) with or without cetuximab (250 mg/m2 weekly).
In the experimental arm, cetuximab (500 mg/m2 every 2
weeks) was continued postoperatively for 12 weeks as
adjuvant treatment [15]. Eligibility criteria were patients
with resectable esophageal squamous cell or adenocar-
cinoma (including Siewert II) with the Union for
International Cancer Control (UICC) TNM stages cT2+,
cT3 cNx or cT4a cNx, 18–75 years old and with an
Eastern Co-operative Oncology Group (ECOG) perform-
ance status of 0–1. Cervical tumors and tumors within
the first 5 cm of the thoracic esophagus were not eli-
gible. Radiotherapy was delivered in 25 daily fractions of
1.8 Gy to a total dose of 45 Gy with weekly concomitant
chemotherapy. The clinical target volume (CTV) was de-
fined by anatomically adapted margins around the
macroscopic tumor of 3.5 cm longitudinally and 1 cm ra-
dially. Additionally, all positive nodes were covered and
the coeliac nodes were included in the CTV for distal
esophageal cancers. Planning treatment volume (PTV)
was 1 cm. Median time between the end of radiotherapy
and surgery were 6 weeks (range: 3–18 weeks). The pri-
mary endpoint was progression-free survival (PFS), sec-
ondary endpoints were overall survival (OS), time to
locoregional and distant failure after R0 resection, post-
operative complications, in-hospital mortality, the rate of
R0 resection and pathological remission.
With a median follow-up of 4 years, the study showed a
significant improvement of the time to loco-regional fail-
ure after R0-resection by the addition of cetuximab to
trimodality therapy (HR 0.53 (0.31–0.90), p = 0.017). Add-
itionally, there was a non-significant, but obvious trend to-
wards improved OS in the experimental arm with a
median OS of 5.1 versus 3.0 years (HR 0.73 (0.52–1.01),
p = 0.055). There was no statistically significant improve-
ment of progression-free survival (p = 0.13) [15].
For our substudy, only patients from four sites in
Switzerland, Kantonsspital St. Gallen, Inselspital Bern,
Universitätsspital Zürich and Kantonsspital Winterthur,
were included.
Adverse events were collected according to the
Common Terminology Criteria for Adverse Events
(CTCAE) version 4.0.
CT-based assessment of skeletal muscle mass
Skeletal muscle surface on cross-sectional CT images has
been demonstrated to correlate well with total body
muscle mass [16] and is considered the gold standard for
body composition analysis in cancer patients [3]. A single
cross-sectional abdominal CT slice at the height of the
third lumbar vertebra (L3) was used as representative for
the whole body composition (Fig. 1) [17, 18]. The follow-
ing CT scans were used for the analysis: CT from the ini-
tial staging PET-CT before induction chemotherapy (per
protocol within 6 weeks before the start of neoadjuvant
therapy); radiotherapy planning CT after induction chemo
(immuno) therapy and before radiochemo (immuno) ther-
apy (RC(I)T, week six of neoadjuvant therapy); re-staging
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CT after radiotherapy and before surgery (week 12–15 of
neoadjuvant therapy).
Image analysis of anonymized CT slices was per-
formed with a dedicated research software (Slice-O-
Matic™, Tomovision, Magog, Canada) as described previ-
ously [19].
Skeletal muscle was identified anatomically and quan-
tified using Hounsfield unit (HU) thresholds (− 29 to +
150) [20] and contains at the L3 level psoas, paraspinal
muscles (erector spinae, quadratus lumborum), and ab-
dominal wall muscles (transversus abdominus, external
and internal obliques, rectus abdominus) [21]. The
cross-sectional muscle area at this height (cm2) was nor-
malised for stature (L3 skeletal muscle index, cm2/m2),
as it is linearly related to whole-body muscle mass [16].
Additionally, data on cross-sectional total adipose tissue
was obtained as previously described [22]. Sarcopenia
was defined by previously published sex-specific cut-offs
for L3 skeletal muscle index (men: 43 m2/m2 for body
mass index (BMI) < 25 kg/m2, 53 cm2/m2 for BMI ≥ 25
kg/m2; women: 41 cm2/m2) [21]. Additionally, we per-
formed in 57 male patients a receiver operating charac-
teristics (ROC) curve analysis in order to investigate the
additional value of population-specific cut-off values for
sarcopenia.
Statistical analysis
Sarcopenia was assessed for patients from the aforemen-
tioned institutions in Switzerland. A total of 61 patients
had sarcopenia assessment for at least two time points.
Baseline sarcopenia was available for 60 patients. The
loss of muscle mass between baseline and surgery was
calculated as the difference in skeletal muscle index be-
tween start of induction chemo (immuno) therapy and
surgery.
Sarcopenia endpoints were summarized descriptively
using median and range for continuous data and fre-
quency and percentage for categorical data overall as
well as separately by treatment arm.
Continuous data was summarized using median and
range and compared between subgroups using Wilcoxon
rank-sum tests. Categorical data was summarized using
frequency counts and percentages and compared be-
tween subgroups using Fisher’s exact tests. Time-to-
event endpoints were summarized by the median and
corresponding 95% confidence interval (CI) using the
Kaplan-Meier method. The number and type of events
were presented descriptively by frequency and percent-
age. Comparisons of time-to-event endpoints between
subgroups were performed using the log-rank test.
All analyses were performed using SAS 9.4 and R
3.4.3.
Results
Analysis using standard cut-off values for sarcopenia
Sixty-one patients from four centers in Switzerland
were included in this substudy and showed similar
patient characteristics and tumor stage and histology
compared to the whole SAKK 75/08 study population
(Table 1) [15].
Skeletal muscle surface derived from CT imaging was
available for 98% of the included patients at baseline sta-
ging, for 89% before neoadjuvant RC(I)T and for 100%
after neoadjuvant treatment before surgery.
Sarcopenia defined by published cut-offs [21] was
found at baseline in 29.5% of the included patients. We
found no significant differences between the group of
sarcopenic and non-sarcopenic patients regarding body
mass index, age, performance status, histologic type, T
stage and N stage.
Over the course of neoadjuvant treatment there was a
significant reduction of the L3 muscle index from a
median of 52.2 to 46.5 cm2/m2 (p < 0.0001). Also, total
adipose tissue was significantly reduced over the neoad-
juvant treatment course (p = 0.041). The prevalence of
sarcopenia was similar in both treatment arms of the
study at the initial radiological staging (p = 1.0) and pro-
gressed significantly under neoadjuvant therapy from
Fig. 1 Cross-sectional abdominal CT on the level of the third lumbal vertebra. Skeletal muscle surface is delineated in a non-sarcopenic patient
(a) and in a sarcopenic patient (b)
Panje et al. Radiation Oncology          (2019) 14:166 Page 3 of 7
29.5 to 63.9% in the whole investigated population
(p < 0.0001, see Table 2).
Association of sarcopenia with adverse events during
neoadjuvant therapy and surgery
Sarcopenia at baseline according to published cut-offs
from Martin et al. [21] showed a significantly higher rate
of grade ≥ 3 adverse events during RC(I)T and a non-sig-
nificant trend to higher postoperative morbidity (Table
3). We observed no difference in toxicity during induc-
tion chemotherapy in sarcopenic and non-sarcopenic pa-
tients. The only two cases of postoperative death
occurred in the non-sarcopenic patient group. Sarcope-
nia before RC(I)T assessed at the radiotherapy planning
CT showed a significantly increased grade ≥ 3 toxicity
during RC(I)T (80.0% vs. 34.8%, p = 0.002). Sarcopenia
assessed directly before surgery showed a numerical, but
non-significant difference in surgical complications
(56.4% vs. 36.4%, p = 0.18).
Feasibility of therapy
Neoadjuvant therapy and surgery were feasible both in
sarcopenic and non-sarcopenic patients in the majority
of patients without statistically significant difference
between these groups: all patients completed induction
chemotherapy and 92% neoadjuvant radiochemotherapy.
Surgery was performed in 97%. The frequency of hos-
pital admissions during neoadjuvant therapy was not
significantly higher in sarcopenic patients. We observed
no significant difference in postoperative hospitalization
in patients with sarcopenia at baseline (median days 20.5
vs. 18.5, p = 0.43) and when sarcopenia was assessed
directly before surgery (20 vs. 19.5 days, p = 0.69). Also,
there was no significant difference in time spent on
the intensive care unit postoperatively between sarco-
penic and non-sarcopenic patients defined at baseline
(p = 0.58).
Impact of sarcopenia on oncological outcome
We observed no significant difference in progression-
free survival (PFS, p = 0.44) and overall survival (OS,
p = 0.72, see Fig. 2) between sarcopenic and non-sarco-
penic patients when the muscle index at baseline was
considered.
Using population-specific cut-offs for sarcopenia de-
fined by ROC analysis gave similar results compared to
the standard cut-offs by Martin et al. [21]: Sarcopenia
defined by a L3 skeletal muscle index of 47.5 cm2/m2 or
lower before RC(I)T resulted in a significantly higher
rate of grade ≥ 3 adverse events during RC(I)T (78.3% vs.
38.5%; p = 0.009). There was no significant correlation
between sarcopenia defined by the population-specific
cutoff at baseline and OS (p = 0.57).
Discussion
There is a growing body of literature on the impact of
low skeletal muscle mass, i.e. sarcopenia on toxicity and
outcome in patients treated for esophageal cancer [7].
Several retrospective patient series have been published
with inconsistent results regarding the correlation of
Table 1 Patient characteristics in sarcopenia substudy and
whole SAKK 75/08 population
SAKK 75/08
whole population
Sarcopenia substudy
population
n 300 61
Age (years; median
and range)
61 (36, 75) 61 (38, 75)
Sex
Female 37 (12.3%) 4 (6.6%)
Male 263 (87.7%) 57 (93.4%)
Clinical stage
T2 N+ 44 (14.7%) 16 (26.2%)
T3 N0 31 (10.3%) 2 (3.3%)
T3/4 N+ 225 (75.0%) 43 (70.5%)
Performance Status
0 189 (63.0%) 32 (52.5%)
1 109 (36.3%) 29 (47.5%)
Histologic Type
AC 189 (63.0%) 50 (82.0%)
SCC 111 (37.0%) 11 (18.0%)
AC Adenocarcinoma, SCC Squamous cell carcinoma. Baseline L3 muscle index
was not assessable in one patient
Table 2 Sarcopenia endpoints (n = 61)
Variable Before induction
therapy (baseline)
Before RC(I)T Before surgery Change between
baseline and surgery
(p-value*)
Skeletal muscle surface (cm2) 160.1 (72.8, 211.4) 144.9 (66.5, 198.0) 144.4 (61.4, 187.0) −14.6 (p < 0.0001)
Total adipose tissue (cm2) 294.9 (24.1, 823.6) 292.4 (29.9, 841.1) 285.7 (64.1, 756.6) −10.7 (p = 0.041)
L3 skeletal muscle index (cm2/ m2) 52.2 (26.7, 75.8) 47.3 (24.4, 66.9) 46.5 (22.6, 67.1) −5.0 (p < 0.0001)
Sarcopenia 29.5% 49.2% 63.9% + 34.4% (p < 0.0001)
RC(I)T Radiochemo (immuno) therapy. Values are depicted as median (range). Sarcopenia was defined according to established sex-specific cut-off values [21]. *Mc
Nemar test for categorical variables and Wilcoxon rank-sum test for continuous variables
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sarcopenia and impaired survival as well as increased
adverse events [7, 8].
To our knowledge, our study is the first association of
skeletal muscle mass with prospectively collected CTCAE
adverse events and survival data in patients undergoing
curatively intended therapy for locally advanced esopha-
geal cancer. We investigated the role of sarcopenia in a
selected, homogeneous patient population with good
performance status and no severe comorbidities which
met the inclusion criteria of the SAKK 75/08 phase III
trial.
During the course of neoadjuvant therapy we observed
a statistically significant loss of muscle mass and conse-
quently increased percentage of sarcopenic patients in
the whole study population. These findings have also
been described in previous retrospective studies and
have been associated with inferior survival [23, 24].
In our substudy of the phase III trial SAKK 75/08, we
found significantly increased adverse events during
RC(I)T and a non-significant trend for increased surgical
morbidity in sarcopenic patients. However, sarcopenic
patients showed the same treatment compliance includ-
ing surgery as non-sarcopenic patients and showed no
increased postoperative mortality. Due to small sample
size and exploratory nature of our analysis, correlation
of long-term outcome regarding survival should be
interpreted with caution.
A recent meta-analysis of several previously published
retrospective series found a negative impact of sarcope-
nia on survival in patients with esophageal cancer [7].
There was no significant association of sarcopenia with
postoperative morbidity except for pulmonary infections
[7]. Most of the previous published series reporting in-
creased toxicity or mortality for sarcopenic patients were
retrospective in nature and included a heterogeneous
population of patients with non-metastatic esophageal
cancer. In contrast, our population met concise study in-
clusion criteria and was able to undergo trimodality
therapy [15]. This is a significant selection bias com-
pared to the general population of patients with locally
advanced esophageal cancer. We cannot exclude that
sarcopenia served in previously published patient series
Table 3 Adverse events and surgical complications by
sarcopenia at baseline
Variable No sarcopenia
(N = 29)
Sarcopenia
(N = 31)
n (%) n (%) p-value
AE grade≥ 3 during induction
chemotherapy
0.78
No 22 (52.4%) 8 (44.4%)
Yes 20 (47.6%) 10 (55.6%)
AE grade≥ 3 during RC(I)T 0.041
No 20 (47.6%) 3 (16.7%)
Yes 22 (52.4%) 15 (83.3%)
Overall surgical complications 0.16
No 24 (57.1%) 6 (33.3%)
Yes 18 (42.9%) 12 (66.7%)
Hospitalization during
neoadjuvant therapy
1
No 5 (11.9%) 2 (11.1%)
Yes 37 (88.1%) 16 (88.9%)
Duration of postoperative
hospitalization
Median (range) 18.5
(10.0, 144.0)
20.5
(10.0, 49.0)
0.43
AE Adverse event, RC(I)T Radiochemo (immune) therapy
Fig. 2 Kaplan-Meier plot for OS by sarcopenia at baseline (p = 0.72)
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as a surrogate parameter for poor general condition and
advanced tumor stage and may therefore have a more
pronounced effect on oncologic outcome than in our
study. This hypothesis is supported by other studies
which did not find a significantly inferior survival in sar-
copenic esophageal cancer patients which were able to
undergo esophagectomy [10, 11, 14].
There is only limited data on the role of sarcopenia
regarding neoadjuvant radiochemotherapy. Our results
showing increased toxicity during neoadjuvant radio-
chemotherapy in sarcopenic patients have to be
highlighted as most studies were mainly focused on
postoperative morbidity and survival [7]. In line with
our findings, a retrospective series by Murimwa et al.
sarcopenic patients identified by the less commonly
used L4 psoas muscle index showed increased acute
toxicity without negative impact on survival [12].
However, several publications question the validity of
psoas muscle index [25, 26].
Our study had limitations. First, data were only avail-
able for a subgroup of the SAKK 75/08 trial at four sites
in Switzerland, but patient characteristics were similar to
the whole study population. However, our study may be
underpowered to detect small differences between the
group of sarcopenic and non-sarcopenic patients, par-
ticularly regarding outcome. Our analysis might be
biased by different intervals between the three time
points of skeletal muscle mass assessment: The last CT-
based measurement was done directly before surgery
with a median interval of 6 weeks after the end of
RC(I)T, but 19% of the patients had an interval longer
than 7 weeks. Additionally, it is possible that our study
underestimates the actual loss of muscle mass during
RC(I)T, as patients had time to recover in the interval
until surgery. Also, patients from both treatment arms,
i.e. patients receiving trimodality treatment with or with-
out cetuximab, were included. The prevalence of sarco-
penia was similar in both treatment arms in our
substudy, nevertheless we cannot exclude any interaction
of cetuximab with sarcopenia. While the SAKK 75/08
control arm is standard in many Swiss centers, neoadju-
vant RCT for esophageal cancer is more commonly per-
formed according to the less intense CROSS protocol
[27]. It is not clear whether the increased toxicity of neo-
adjuvant RCT in sarcopenic patients is as pronounced as
in our study when the CROSS regimen is used (41.4 Gy
in 23 fractions and weekly chemotherapy with carbopla-
tin and paclitaxel without induction chemotherapy) [27].
Finally, we were not able to perform separate analyses
for adenocarcinoma and squamous cell carcinoma of the
esophagus due to the limited patient number.
In conclusion, our findings show that trimodality ther-
apy in locally advanced esophageal cancer according to
the SAKK 75/08 protocol is also feasible in sarcopenic
patients despite higher grade 3–4 toxicity during neoad-
juvant RC(I)T. The role of sarcopenia in esophageal can-
cer needs to be further investigated in order to improve
the identification of patients at risk for increased tox-
icity, as these patients may benefit from more intensive
monitoring and supportive therapy.
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